分析

KMI Korean Medical Institute contributed 300 million KRW to fund delivery of medicines and medical devices for rare disease and type 1 diabetes patients, announced by the Ministry of Health and Welfare.

Pharma distributors in South Korea are changing delivery dates around the July 17 Constitution Day holiday; pharmacies should check each supplier’s cut‑off times to avoid order issues.

While a weak won usually boosts exporters, pharma and biotech firms see mixed effects as foreign revenue growth is offset by rising foreign‑currency costs for raw materials, debt and liabilities.

Hanmi’s Rosuzet, a fixed‑dose combo of ezetimibe and rosuvastatin, is expanding its presence in the Korean hyperlipidemia market, backed by strong clinical data and real‑world prescribing outcomes.

Venture capital invested over $9 billion in biotech this year, with more than $3.9 billion directed to cancer and immune‑disease drug developers, accounting for over 40% of deals.

Global medical aesthetic company Baim opened the JUVELOOK flagship cafe in Seoul’s Samseong‑dong, offering branded drinks, desserts, skincare products and merchandise.

BaroPharm marks its 5‑year service anniversary by running a July‑long “Baroland” promotion for pharmacy members, offering access to platform features and expressing gratitude.

Pamgen Science introduced ‘VitainB’, Korea’s first sustained‑release vitamin B complex, targeting the high‑dose vitamin market.

Pharmacy chain Optima introduces the ‘Lidorcel Celebrity’ dermo‑cosmetic brand, co‑developed with Liwon Dermatology, to support post‑procedure home skin care.

Six biotech firms from Chungcheongbuk-do, supported by KBIOHealth, reported $40.59 million in export discussions and $1 million in investment talks at BIO USA 2026 in San Diego.

Vertex Pharma announced a $10 billion acquisition of Crinetics, adding the potential blockbuster Palsonify and ACTH‑receptor antagonist atumelnant for congenital adrenal hyperplasia.

Samjin Pharmaceutical announced a ~15% increase in supply prices for its Trestan capsule and chewable tablet lines, effective July 1, 2026, the first hike since Dec 2022.